| Literature DB >> 11725377 |
Abstract
Hepatitis C is a major health problem. In recent years, the treatment of choice is alpha-interferon in combination with ribavirin. For patients with failure of this treatment the therapy with consensus or pegylated interferons, in monotherapy or in combination with ribavirin, present other possibilities. We can expect the development more potent antiviral drugs or immune modulators for patients, which are primary resistant to alpha-interferon. (Tab. 3, Ref. 31)Entities:
Mesh:
Substances:
Year: 2001 PMID: 11725377
Source DB: PubMed Journal: Bratisl Lek Listy ISSN: 0006-9248 Impact factor: 1.278